Last reviewed · How we verify
NCT05829187: MCHUPF
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
Phase 2 trial testing Dihydroartemisinin in Uncomplicated Plasmodium Falciparum in 36 participants. Completed in 31 December 2022.
31 December 2022
Quick facts
| Lead sponsor | Syamsudin Abdillah,Ph.D, Pharm D |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 1 November 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- Dihydroartemisinin — full drug profile →
- Piperaquine — full drug profile →
- Primaquine — full drug profile →
- Momordica Charantia Extract — full drug profile →
Conditions studied
- Uncomplicated Plasmodium Falciparum — all drugs for Uncomplicated Plasmodium Falciparum →
Sponsor
Syamsudin Abdillah,Ph.D, Pharm D — full company profile →
Who can join
Adults 18 to 60, any sex, with Uncomplicated Plasmodium Falciparum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently, the first-line combination of artemisinin, piperaquine and prima-quine is quite effective in controlling malaria, however, the threat of spread of drug-resistant parasites has been reported. A study is conducted to assess the efficacy and safety extract of bitter melon (Momordica charantia/MC) regimens compared to the combination of dihydroartemisinin piperaquine primaquine (DHP+PQ) on the sexual and asexual stage of P. Falciparum uncomplicated in Sumba Barat Daya District, Indonesia
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05829187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dihydroartemisinin
Trials testing the same drug.
- NCT06842524 — Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome · Phase 2 · recruiting
- NCT06417099 — Efficacy of Dihydroartemisinin for Treating PCOS · Phase 2 · completed
- NCT05465135 — The Effect of Dihydroartemisinin in PCOS · Phase 4 · completed
- NCT06036030 — Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax · Phase 2 · completed
Other Syamsudin Abdillah,Ph.D, Pharm D trials
Trials by the same sponsor.
- NCT06036030 — Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05829187 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Syamsudin Abdillah,Ph.D, Pharm D
- Last refreshed: 16 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05829187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing